Is Vertex Pharmaceuticals (VRTX) Offering Value After Recent Pipeline Milestones And Mixed Share Performance?

Simply Wall St.14:08

Investors may be considering whether Vertex Pharmaceuticals at around US$441 per share is offering fair value or if that price reflects a potential premium for growth prospects. The stock is up 1.1% ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2628613887?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/36235-main-header/1756253398031","is_english":true,"pubTime":"2026-04-19 14:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2628613887","market":"sg","top_or_hot":-1,"title":"Is Vertex Pharmaceuticals (VRTX) Offering Value After Recent Pipeline Milestones And Mixed Share Performance?","media":"Simply Wall St.","content":"<div>\n<p>Investors may be considering whether Vertex Pharmaceuticals at around US$441 per share is offering fair value or if that price reflects a potential premium for growth prospects. The stock is up 1.1% ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/news/is-vertex-pharmaceuticals-vrtx-offering-value-after-recent-p\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Vertex Pharmaceuticals (VRTX) Offering Value After Recent Pipeline Milestones And Mixed Share Performance?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Vertex Pharmaceuticals (VRTX) Offering Value After Recent Pipeline Milestones And Mixed Share Performance?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-19 14:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/news/is-vertex-pharmaceuticals-vrtx-offering-value-after-recent-p><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors may be considering whether Vertex Pharmaceuticals at around US$441 per share is offering fair value or if that price reflects a potential premium for growth prospects. The stock is up 1.1% ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/news/is-vertex-pharmaceuticals-vrtx-offering-value-after-recent-p\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B19Z3B42.SGD","symbol_name":"Legg Mason ClearBridge - Value A Acc SGD","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/news/is-vertex-pharmaceuticals-vrtx-offering-value-after-recent-p","article_id":"2628613887","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/36235-main-header/1756253398031"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/news/is-vertex-pharmaceuticals-vrtx-offering-value-after-recent-p","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2628613887","pubTimestamp":1776578939,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Investors may be considering whether Vertex Pharmaceuticals at around US$441 per share is offering fair value or if that price reflects a potential premium for growth prospects.\nThe stock is up 1.1% over the last week, while the 1-year return is a 9.8% decline after a longer-term gain of 102.5% over 5 years.\nRecent headlines have focused on Vertex's pipeline progress and regulatory milestones, which can influence how investors think about future cash flows and risk. These updates help frame...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU1815336091.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AUP\" (USD) INC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4023":"应用软件","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","BK4532":"文艺复兴科技持仓","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","VERX":"Vertex, Inc.","LU0058720904.USD":"联博国际健康护理基金A","BK4567":"ESG概念","BK4585":"ETF&股票定投概念","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4139":"生物科技","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4533":"AQR资本管理(全球第二大对冲基金)","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU0566484027.USD":"安本美国小盘成长股","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","IE00BZ9MQY76.HKD":"FTGF CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (HKD) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1674673691.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (USD) INC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU1674673428.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AC\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","BK4588":"碎股","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU0079474960.USD":"联博美国增长基金A","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","VRTX":"福泰制药","LU0757428866.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AE\" (USD) ACC"},"translate_title":"Vertex Pharmaceuticals(VRTX)在最近的管道里程碑和好坏参半的股票表现之后是否具有价值？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VRTX":1.5,"VERX":1.5,"DCF":1},"content_text":"Investors may be considering whether Vertex Pharmaceuticals at around US$441 per share is offering fair value or if that price reflects a potential premium for growth prospects. The stock is up 1.1% over the last week, while the 1-year return is a 9.8% decline after a longer-term gain of 102.5% over 5 years. Recent headlines have focused on Vertex's pipeline progress and regulatory milestones, which can influence how investors think about future cash flows and risk. These updates help frame why the share price has moved up in the short term and down over the past year. Vertex currently has a valuation score of 4 out of 6. The following sections explore how different valuation approaches assess the stock and then conclude with a broader perspective on what that score may indicate.  Find out why Vertex Pharmaceuticals's -9.8% return over the last year is lagging behind its peers. AdvertisementApproach 1: Vertex Pharmaceuticals Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow, or DCF, model takes forecasts of a company’s future cash flows and discounts them back to today, aiming to estimate what the business could be worth now based on those projected dollars. For Vertex Pharmaceuticals, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is about $3.18b. Analysts provide free cash flow estimates out to 2030, with Simply Wall St extrapolating beyond the typical 5 year analyst horizon. Within these projections, free cash flow for 2030 is modeled at $7.57b, with intermediate years between 2026 and 2035 ranging from roughly $4.92b to $10.02b before discounting. When all those projected cash flows are discounted back and summed, the DCF model arrives at an estimated intrinsic value of about US$739.82 per share. Compared with a current share price around US$441, this set of assumptions suggests the stock is about 40.4% below the model’s estimate of intrinsic value. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests Vertex Pharmaceuticals is undervalued by 40.4%. Track this in your watchlist or portfolio, or discover 60 more high quality undervalued stocks. VRTX Discounted Cash Flow as at Apr 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Vertex Pharmaceuticals. Approach 2: Vertex Pharmaceuticals Price vs Earnings For profitable companies, the P/E ratio is a useful way to relate what you pay for each share to the earnings that company is currently generating. It helps you see how many dollars the market is willing to pay today for each dollar of earnings. What counts as a “normal” P/E depends on how the market views a company’s growth potential and risk. Higher expected growth or lower perceived risk can support a higher P/E, while lower growth or higher risk usually points to a lower P/E being more appropriate. Vertex Pharmaceuticals trades on a P/E of 28.39x. That sits above the Biotechs industry average P/E of 17.10x, but below the peer group average of 37.52x. Simply Wall St’s “Fair Ratio” for Vertex is 27.46x. This Fair Ratio is a proprietary estimate of what the P/E might be given factors such as earnings growth, industry, profit margins, market cap and company specific risks. Because it adjusts for these fundamentals, it can be more tailored than a simple comparison with industry or peer averages. Vertex’s actual P/E of 28.39x is close to the Fair Ratio of 27.46x, which points to the shares trading around a level consistent with those underlying factors. Result: ABOUT RIGHT NasdaqGS:VRTX P/E Ratio as at Apr 2026 P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies. Upgrade Your Decision Making: Choose your Vertex Pharmaceuticals Narrative Earlier it was mentioned that there is an even better way to understand valuation. Narratives are Simply Wall St's way for you to attach a clear story about Vertex Pharmaceuticals to the numbers by linking your view of its products, risks and opportunities to a specific forecast for revenue, earnings and margins. You can then compare the Fair Value that falls out of that story with the current price, whether that means aligning with a higher fair value view around US$641 per share or a more cautious stance closer to US$330. Each Narrative on the Community page updates automatically as new news and earnings arrive so you can see, at a glance, how your chosen story about the company translates into a live estimate of what the stock might be worth. For Vertex Pharmaceuticals, however, we will make it really easy for you with previews of two leading Vertex Pharmaceuticals Narratives: These give you a clear bull and bear framing on the same set of facts, so you can decide which view lines up better with your own expectations and risk tolerance. 🐂 Vertex Pharmaceuticals Bull Case Fair value in this bullish narrative: US$641.00 per share. Gap to that fair value from the recent price around US$441.20 is about 31.1%, which this view treats as potential undervaluation if the thesis plays out. Revenue growth assumption used in this narrative: 15.70% a year.  Expects ALYFTREK to become the new cystic fibrosis standard of care over time, replacing TRIKAFTA and supporting higher margins and longer patent protection into the 2030s. Sees JOURNAVX, CASGEVY and the renal and diabetes programs as building a broader franchise, with analysts in this camp modeling earnings of about US$8.6b and a P/E of 22.4x around 2029. Assumes Vertex can keep using its strong balance sheet and cash flows to fund R&D, acquisitions and buybacks, while managing risks from competition, regulation and pricing pressure.  🐻 Vertex Pharmaceuticals Bear Case Fair value in this cautious narrative: about US$403.80 per share. Gap to that fair value from the recent price around US$441.20 is about 9.3%, which this view treats as potential overvaluation if the concerns prove accurate. Revenue growth assumption used in this narrative: 3.16% a year.  Highlights pressure on drug pricing, high treatment costs and tightening evidence requirements as headwinds that could limit pricing power and compress margins over time. Flags concentration in rare genetic diseases, ongoing heavy R&D spend and rising competition in gene editing and cell therapy as sources of earnings volatility and downside risk. Works off a lower price target band around US$344, even while assuming earnings grow to about US$4.8b by 2028 and the stock trades on a P/E of 21.9x, implying that current market expectations may already be demanding.  If you want the full context around both the upside and the risks, including how these narratives tie back to detailed forecasts and valuation work, it is worth reading them side by side before making any portfolio decisions. See what the community is saying about Vertex Pharmaceuticals Do you think there's more to the story for Vertex Pharmaceuticals? Head over to our Community to see what others are saying! NasdaqGS:VRTX 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2628613887","isCrawlerRequest":true}